Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?
Piero Ruscitti, Paola Cipriani, Paola Di Benedetto, et al.
Expert Review of Clinical Immunology (2017) Vol. 13, Iss. 11, pp. 1041-1047
Closed Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

A comprehensive review on adult onset Still's disease
Roberto Giacomelli, Piero Ruscitti, Yehuda Shoenfeld
Journal of Autoimmunity (2018) Vol. 93, pp. 24-36
Closed Access | Times Cited: 345
Recent advances and evolving concepts in Still’s disease
Piero Ruscitti, Luca Cantarini, Peter A. Nigrović, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 2, pp. 116-132
Closed Access | Times Cited: 30
Macrophages with regulatory functions, a possible new therapeutic perspective in autoimmune diseases
Paola Di Benedetto, Piero Ruscitti, Zahava Vadasz, et al.
Autoimmunity Reviews (2019) Vol. 18, Iss. 10, pp. 102369-102369
Closed Access | Times Cited: 118
Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm
Piero Ruscitti, Onorina Berardicurti, Paola Di Benedetto, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 95
Anakinra in children and adults with Still’s disease
Sebastiaan J. Vastert, Yvan Jamilloux, Pierre Quartier, et al.
Lara D. Veeken (2019) Vol. 58, Iss. Supplement_6, pp. vi9-vi22
Open Access | Times Cited: 90
Cytokine storm syndrome in severe COVID-19
Piero Ruscitti, Onorina Berardicurti, Annamaria Iagnocco, et al.
Autoimmunity Reviews (2020) Vol. 19, Iss. 7, pp. 102562-102562
Open Access | Times Cited: 79
Adult-Onset Still’s Disease: Clinical Aspects and Therapeutic Approach
Stylianos Tomaras, Carl Christoph Goetzke, Tilmann Kallinich, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 4, pp. 733-733
Open Access | Times Cited: 63
Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort
Piero Ruscitti, Daniela Iacono, Francesco Ciccia, et al.
The Journal of Rheumatology (2018) Vol. 45, Iss. 6, pp. 864-872
Open Access | Times Cited: 78
Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations
Piero Ruscitti, Paola Di Benedetto, Onorina Berardicurti, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 52
The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature
Roberto Giacomelli, Jurgen Sota, Piero Ruscitti, et al.
Clinical and Experimental Rheumatology (2021) Vol. 39, Iss. 1, pp. 187-195
Open Access | Times Cited: 47
Parenchymal lung disease in adult onset Still’s disease: an emergent marker of disease severity—characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients
Piero Ruscitti, Onorina Berardicurti, Daniela Iacono, et al.
Arthritis Research & Therapy (2020) Vol. 22, Iss. 1
Open Access | Times Cited: 44
Tocilizumab for the treatment of adult-onset Still’s disease
Santos Castañeda, Dolores Martínez-Quintanilla, J. L. Martín-Varillas, et al.
Expert Opinion on Biological Therapy (2019) Vol. 19, Iss. 4, pp. 273-286
Open Access | Times Cited: 43
Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still’s disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort
Paola Di Benedetto, Paola Cipriani, Daniela Iacono, et al.
PLoS ONE (2020) Vol. 15, Iss. 7, pp. e0235326-e0235326
Open Access | Times Cited: 43
A review of the pleiotropic actions of the IFN-inducible CXC chemokine receptor 3 ligands in the synovial microenvironment
Luna Dillemans, Lien De Somer, Barbara Neerinckx, et al.
Cellular and Molecular Life Sciences (2023) Vol. 80, Iss. 3
Open Access | Times Cited: 14
H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome
Piero Ruscitti, Paola Cipriani, Paola Di Benedetto, et al.
Clinical & Experimental Immunology (2017) Vol. 191, Iss. 2, pp. 220-228
Open Access | Times Cited: 44
Pathogenesis of adult onset still’s disease: current understanding and new insights
Piero Ruscitti, Roberto Giacomelli
Expert Review of Clinical Immunology (2018) Vol. 14, Iss. 11, pp. 965-976
Closed Access | Times Cited: 44
Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study
Piero Ruscitti, Paola Cipriani, Vasiliki Liakouli, et al.
Medicine (2019) Vol. 98, Iss. 15, pp. e15123-e15123
Open Access | Times Cited: 39
Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still’s disease
Piero Ruscitti, Francesco Ursini, Onorina Berardicurti, et al.
Lara D. Veeken (2022) Vol. 62, Iss. 1, pp. 321-329
Closed Access | Times Cited: 21
Activation mechanisms of monocytes/macrophages in adult-onset Still disease
Hiroto Tsuboi, Seiji Segawa, Mizuki Yagishita, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 20
Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody–positive Dermatomyositis-associated Interstitial Lung Disease
Tomoyuki Fujisawa, Hironao Hozumi, Hideki Yasui, et al.
The Journal of Rheumatology (2019) Vol. 46, Iss. 8, pp. 935-942
Open Access | Times Cited: 35
Systematic review on the use of biologics in adult-onset still's disease
Bruno Fautrel, Jacoby Patterson, Catherine Bowe, et al.
Seminars in Arthritis and Rheumatism (2022) Vol. 58, pp. 152139-152139
Open Access | Times Cited: 18
Toward a personalized therapy of Still’s disease based on immunologic endotypes: a narrative review
Po‐Ku Chen, Shiow-Jiuan Wey, Der‐Yuan Chen
Expert Review of Clinical Immunology (2025)
Closed Access
Tofacitinib as a possible treatment in macrophage activation syndrome: a pilot single-center study in China
Weilin Xie, Qing‐Yan Liu, Yanchun Tang, et al.
Clinical Rheumatology (2025)
Closed Access
Impact of COVID-19 pandemic on SLE: beyond the risk of infection
Alice Horisberger, Laura Moi, Camillo Ribi, et al.
Lupus Science & Medicine (2020) Vol. 7, Iss. 1, pp. e000408-e000408
Open Access | Times Cited: 25
The Pathogenic Role of Interferons in the Hyperinflammatory Response on Adult-Onset Still’s Disease and Macrophage Activation Syndrome: Paving the Way towards New Therapeutic Targets
Ilenia Di Cola, Piero Ruscitti, Roberto Giacomelli, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 6, pp. 1164-1164
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top